Read more from Author Melissa Galbraith here: https://globelivemedia.com/author/melissa-galbraith/
Globe Live Media, Thursday, January 28, 2021
The vaccine developed by Pfizer is administered in two doses and the second is inoculated 21 days after receiving the first dose. In this sense, the first data from the follow-up carried out on health workers at the Bambino Gesù hospital in Rome show that 99% of those vaccinated developed antibodies against COVID-19, as published by the Italian newspaper La Reppublica.
AND 7 days after the second dose, antibodies were developed by 100% of those vaccinated. Likewise, according to the aforementioned media, the data are positive in the immunological aspect: after the first week, there was an increase in B cells (those that maintain the production of antibodies) in 80% of the cases.
Efficacy and protection
Carlo Federico Perno, head of Microbiology and Immunology Diagnosis of the hospital, explained in La Reppublica that “these are the first results that confirm the validity of the vaccine approach in terms of efficacy and protection against SARS-CoV-2 in clinical practice. Our knowledge, showing the details of the mechanisms of the immune response to the vaccine, suggests in based on highlights so far that the antibodies produced by vaccination have a fairly long-lasting persistence in the body “.
“However, after what has been observed so far, this research is quite promising and supports the utility of mass vaccination against COVID-19″, concluded the expert.
Melissa Galbraith is the World News reporter for Globe Live Media. She covers all the major events happening around the World. From Europe to Americas, from Asia to Antarctica, Melissa covers it all. Never miss another Major World Event by bookmarking her author page right here.